Abstract Library

#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs

Introduction: NETs overexpress somatostatin receptors (SSTRs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cives M

Authors: Mandriani B, Cives M, Pelle' E, Quaresmini D, Ramello M,

Keywords: CAR T cells, adoptive cellular immunotherapy, NETs,

#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression

Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,

Keywords: neuroendocrine, estrogen, progesterone, clinical trial,

#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Matheos de Lima B

Authors: Arruda Matheos de Lima B, Gonçalves R, Romano Gaspar P, Linhares Riello de Mello E, Oliveira Albagli R,

Keywords: peptide receptor radionuclide therapy, lutetium, collateral effects, hepatotoxicity, neuroendocrine tumor, hepatic steatosis,